Chabiotech Co Ltd is engaged in the manufacturing of biological products.
2002
n/a
LTM Revenue n/a
LTM EBITDA n/a
$716M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Chabiotech has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Chabiotech achieved revenue of $712M and an EBITDA of $51.8M.
Chabiotech expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Chabiotech valuation multiples based on analyst estimatesFY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $650M | $712M | XXX | XXX | XXX |
Gross Profit | $139M | $188M | XXX | XXX | XXX |
Gross Margin | 21% | 26% | XXX | XXX | XXX |
EBITDA | $47.8M | $51.8M | XXX | XXX | XXX |
EBITDA Margin | 7% | 7% | XXX | XXX | XXX |
Net Profit | -$32.4M | -$5.7M | XXX | XXX | XXX |
Net Margin | -5% | -1% | XXX | XXX | XXX |
Net Debt | $196M | $228M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Chabiotech's stock price is KRW 9470 (or $6).
Chabiotech has current market cap of KRW 578B (or $394M), and EV of KRW 1.05T (or $716M).
See Chabiotech trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$716M | $394M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Chabiotech has market cap of $394M and EV of $716M.
Chabiotech's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Chabiotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Chabiotech and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $716M | XXX | XXX | XXX |
EV/Revenue | 1.0x | XXX | XXX | XXX |
EV/EBITDA | 13.8x | XXX | XXX | XXX |
P/E | -71.7x | XXX | XXX | XXX |
P/E/Growth | n/a | XXX | XXX | XXX |
EV/FCF | -7.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpChabiotech's NTM/LTM revenue growth is n/a
Chabiotech's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Chabiotech's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Chabiotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Chabiotech and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | 10% | XXX | XXX | XXX | XXX |
EBITDA Margin | 7% | XXX | XXX | XXX | XXX |
EBITDA Growth | 8% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
Opex per Employee | n/a | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | 10% | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
Opex to Revenue | 32% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Chabiotech acquired XXX companies to date.
Last acquisition by Chabiotech was XXXXXXXX, XXXXX XXXXX XXXXXX . Chabiotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was Chabiotech founded? | Chabiotech was founded in 2002. |
Where is Chabiotech headquartered? | Chabiotech is headquartered in South Korea. |
Who is the CEO of Chabiotech? | Chabiotech's CEO is Mr. Sang-Hoon Oh. |
Is Chabiotech publicy listed? | Yes, Chabiotech is a public company listed on KRX. |
What is the stock symbol of Chabiotech? | Chabiotech trades under 085660 ticker. |
When did Chabiotech go public? | Chabiotech went public in 2005. |
Who are competitors of Chabiotech? | Similar companies to Chabiotech include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
What is the current market cap of Chabiotech? | Chabiotech's current market cap is $394M |
What is the current revenue growth of Chabiotech? | Chabiotech revenue growth between 2023 and 2024 was 10%. |
Is Chabiotech profitable? | Yes, Chabiotech is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.